Bioadaptives (BDPT) Cash & Equivalents (2019 - 2025)
Historic Cash & Equivalents for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to $59273.0.
- Bioadaptives' Cash & Equivalents rose 3503.98% to $59273.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $59273.0, marking a year-over-year increase of 3503.98%. This contributed to the annual value of $137470.0 for FY2024, which is 12619.13% up from last year.
- According to the latest figures from Q3 2025, Bioadaptives' Cash & Equivalents is $59273.0, which was up 3503.98% from $210582.0 recorded in Q2 2025.
- Over the past 5 years, Bioadaptives' Cash & Equivalents peaked at $210582.0 during Q2 2025, and registered a low of $235.0 during Q2 2024.
- Its 5-year average for Cash & Equivalents is $60932.4, with a median of $44450.0 in 2022.
- As far as peak fluctuations go, Bioadaptives' Cash & Equivalents plummeted by 9941.43% in 2024, and later skyrocketed by 8950936.17% in 2025.
- Bioadaptives' Cash & Equivalents (Quarter) stood at $82936.0 in 2021, then plummeted by 69.37% to $25405.0 in 2022, then soared by 139.23% to $60776.0 in 2023, then skyrocketed by 126.19% to $137470.0 in 2024, then plummeted by 56.88% to $59273.0 in 2025.
- Its Cash & Equivalents stands at $59273.0 for Q3 2025, versus $210582.0 for Q2 2025 and $39564.0 for Q1 2025.